<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PAROMOMYCIN SULFATE <img border="0" src="../images/pr.gif"/></span><br/>(par-oh-moe-mye'sin)<br/><span class="topboxtradename">Humatin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">aminoglycoside antibiotic</span>; <span class="classification">amebicide</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Aminoglycoside antibiotic produced by certain strains of <i>Streptomyces rimosus</i> with broad spectrum of antibacterial activity closely paralleling that of kanamycin and neomycin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Exerts direct bactericidal and amebicidal action, primarily in lumen of GI tract. Ineffective against extraintestinal amebiasis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute and chronic intestinal amebiasis and to rid bowel of nitrogen-forming bacteria in patients with hepatic coma; used preoperatively
         to suppress intestinal flora. Also tapeworm infestation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Intestinal obstruction; impaired kidney function; pregnancy (category C) and lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>GI ulceration.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Intestinal Amebiasis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2535 mg/kg divided in 3 doses for 510 d<br/><br/><span class="indicationtitle">Hepatic Coma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 g/d in 24 divided doses for 56 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give after meals to prevent gastric distress.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, vertigo. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea, abdominal cramps,</span> steatorrhea, <span class="speceff-common">nausea, vomiting, heartburn,</span> secondary enterocolitis. <span class="typehead">Skin:</span> Exanthema, rash, pruritus. <span class="typehead">Special Senses:</span> Ototoxicity. <span class="typehead">Urogenital:</span> Nephrotoxicity (in patients with GI inflammation or ulcerations). <span class="typehead">Body as a Whole:</span> Eosinophilia, overgrowth of nonsusceptible organisms. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Prolonged use of paromomycin may cause reduction in <span class="alt">serum cholesterol.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease absorption of <b>cyanocobalamin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from intact GI tract. <span class="typehead">Elimination:</span> In feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. Criterion of cure is absence of amoebae in stool specimens examined at weekly intervals
            for 6 wk after completion of treatment, and thereafter at monthly intervals for 2 y.
         </li>
<li>Monitor for appearance of a superinfection during therapy (see Appendix F).</li>
<li>Lab test: baseline WBC with differential. Repeat if superfiction is suspected.</li>
<li>Monitor closely patients with history of GI ulceration for nephrotoxicity and ototoxicity (see Appendix F). Drug absorption
            can take place through diseased mucosa.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not prepare, process, or serve food until treatment is complete when receiving drug for intestinal amebiasis. Isolation
            is not required.
         </li>
<li>Practice strict personal hygiene, particularly hand washing after defecation and before eating food.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>